Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

Alternate Symbol(s):  OPSSF

OpSens Inc. is engaged in physiological measurements such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and in transcatheter aortic valve replacement (TAVR) in the structural heart market. The Company supplies an optical-based pressure guidewire (OptoWire), a guidewire used in the TAVR procedure (SavvyWire) and a wide range of miniature optical sensors to measure pressure and temperature to be used in a wide range of applications that can be integrated into other medical devices.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RBC

November 1, 2022 Opsens Inc. CFO departure and initial read through from J&J's acquisition of Abiomed TSX: OPS | CAD 2.48 | Outperform | Speculative Risk...read more

New Press Release - OPSENS ANNOUNCES DEPARTURE OF CFO

QUÉBEC, Nov. 1, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that Robin Villeneuve, Chief Financial Officer and...read article.

RE:RE:Sign of expansion

According to my note and observation the parking lot is complete and ready to park 30 additional vehicules. So far, good estimation from my part but I would like to  inform you all what will be...read more

RE:RE:RE:Raymond James - cantechletter.com

I rather think that there  is no more sellers at this range,weak hands have  been fulfilled and the pendulum changed direction. The selling, or lack of is encouraging.  rate and reply

RE:RE:Raymond James - cantechletter.com

Looks as if the few posters here are the only ones reading that RJ updated article . The buying , or lack of , is depressing   rate and reply

Projected revenue in 2023 = $ 44 M

According to Raymond James analyst Rahul Sarugaser Probable  2022 revenue of $ 35 M and 2023 projected revenue of $ 44 M or 25 % increase and EBITDA loss of $9 million.or about the same as this...read more

RE:Raymond James - cantechletter.com

Exactly so PI 01. Good observation . GLTA   rate and reply

RE:Raymond James - cantechletter.com

aagh , spelling , equipment of 3 different companies  rate and reply

Raymond James - cantechletter.com

  I find it interesting that it was used with the equipemt of 3 different companies- Abbott, Edwards and Medtronic - all three potential acquirers IMO. By Jayson...read more

From a relative not too long comment !September 11 2022

''' In summary, Opsens  growth has been exceptional in the last 10 years from $ 8 462 000 to $ 36 271 000 or 428 % increase  and the target to reach $  100 000 000 in 3...read more

New Press Release - OPSENS ANNOUNCES FIRST SAVVYWIRE CLINICAL CASES IN EUROPE AND LAUNCH OF SAFE-TAVI STUDY

QUEBEC CITY, Oct. 26, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced the successful completion of the first cases in a...read article.

RE:RE:RE:My view...

Mon Dieu!!!  Putting all your eggs in one basket is way too risky...   There is absolutely no question that OPS is a great company doing exactly what needs to be done.  No...read more

RE:RE:My view...

'''kind'a betted the farm on it!''' Just to say that betting BIG on OPS is certainly not to the way to invest but it's up to you . You must have read that when you...read more

RE:My view...

I kind of disagree with you,i dont think that OPS value can go to zero. The savvywired has been tested,it works and its. been approoved so there is a value there.And i would mind very much if it goes...read more

My view...

Opsens is good bet! But you have to be confident in the technology they are developing around the ''globe'' Next Financial Report to give us some ''indications ''...read more

RE:RE:Anyone else

I am fully invested and haven't sold a share . The low volume and the downward trend might be good for you to keep adding at lower and lower prices tannin .   rate and reply

RE:Anyone else

Patience ddogold, patience. Only reason to check sp is to determine when to buy more.  rate and reply

Anyone else

Expecting news on contracts or P.O.'s once we received both Health Canada and FDA approvals ? Let's hope there's behind closed door meetings on that front and some firm news coming .  rate and reply

Le fond bu baril

Je crois que le fond du baril en terme de sous-evaluation de l'action a ete atteint autour de 2.25$.Maintenant, avec le devoilement des resultats financiers qui approchent et qui seront...read more